Pneumonia Testing Market

Pneumonia Testing Market Size (2023 to 2028)

The pneumonia testing market size was valued at USD 613.23 million in 2022 and is expected to reach USD 812.43 million by 2028. The market size is projected to grow at a CAGR of 4.8% during the forecast period 2023-2028.

Impact of Covid-19 on the Pneumonia Testing Market:

Pneumonia is type of a lung infection. Pneumonia is an infection that inflames the air sacs in one or both lungs. The air sacs may fill with fluid or pus, causing cough with phlegm or pus, fever, chills, and difficulty breathing. A variety of organisms, including bacteria, viruses, and fungi, can cause pneumonia. Pneumonia testing is a crucial diagnostic tool used to confirm the presence of pneumonia and identify the causative agent for effective treatment. Pneumonia testing can be done by various processes such as physical examination, blood test, sputum culture, bronchoscopy, and fluid sample.

Covid-19 has a significant impact on the pneumonia testing market. Due to the COVID-19 pandemic in 2020, there was a rise in the number of cases of viral pneumonia. The pandemic has brought increased attention to respiratory infections, including pneumonia, as it is one of the leading causes of severe illness and mortality among COVID-19 patients. There was a surge in the number of microbiological tests to check the co-infection in patients with COVID-19-induced pneumonia and accurately diagnose the type of pneumonia to decide the treatment flow and improve patient outcomes. For instance, according to an article published by the Hindu in November 2020, healthcare professionals estimated that nearly 60%-80% of recent pneumonia cases in India were attributed to COVID-19. Furthermore, the COVID-19 pandemic has also accelerated the adoption of point-of-care testing for pneumonia, as it allows for rapid testing and reduces the need for patients to visit healthcare facilities, minimizing the risk of exposure to the virus. The pandemic has also increased the importance of multiplex testing in pneumonia diagnosis, as it allows for the simultaneous detection of multiple pathogens, including SARS-CoV-2, the virus causing COVID-19, and other common pneumonia-causing pathogens. This has led to increased demand for advanced diagnostic technologies that offer multiplex testing capabilities.

Market Drivers:

The key factor that drives the pneumonia testing market is the Significant increase in the prevalence of pneumonia across the globe. This is expected to propel the global market growth. Predominantly, pneumonia is considered one of the most common causes of hospitalization among all infectious. diseases. If the patient is found critical, the patient is hospitalized and further microbiological tests for pneumonia are done. For instance, the American Thoracic Society estimates that about 1.0 million adults in the U.S. seek hospital care yearly due to pneumonia. Pneumonia is more common in children and the elderly. For instance, as per the article released by the United Nations International Children's Emergency Fund, there are about 1,400 instances of pneumonia per 100,000 people worldwide in 2020.

Point of care testing and advancements in the nucleic acid detection sector and technological advancements in pneumonia testing are the major factors propelling the growth of the pneumonia testing market. The advanced multiplex PCR-based platform for diagnosing pneumonia offers higher detection efficiency, thereby reducing cost and time. The global pneumonia diagnostics market is likely to witness healthy growth owing to the increasing investments and initiatives by governments in emerging countries to modernize healthcare infrastructure. The broad availability of rapid molecular diagnostic testing offers insight into pneumonia diagnosis. This helps to drive the pneumonia testing market.

Additionally, some poverty-related factors, such as malnutrition, and lack of safe drinking water and sanitation, contribute to pneumonia-associated mortality among children in developing nations. Thus, a sudden increase in pneumonia-related mortality has raised concern among developing countries' governments to launch programs to increase awareness regarding pneumonia diagnosis to prevent deaths. Developed nations are more concerned regarding pneumonia diagnosis; thus, the American Thoracic Society / Infectious Diseases Society of America, released Community-Acquired Pneumonia (CAP) guidelines. Such pneumonia testing guidelines for pneumonia diagnosis are expected to be taken by developing nations to increase awareness of these testing procedures. Hence, these factors are the drivers for the growth of the pneumonia testing market.

Market Restraints:

One of the major restrictions that decrease the growth of the pneumonia testing market is the high cost associated with advanced training methods such as NAT and PCR. These techniques require highly skilled personnel and specialized high facilities which leads to an increase in the cost of the method used for the pneumonia testing. This can pose a limit on the resource-limited facilities, where affordability and accessibility of advanced testing may be limited. The widespread utilization of X-rays as an essential tool for pneumonia detection limits the growth of the market. Generally, a combination of clinical history, physical examination, and laboratory tests is usually used in the diagnosis of pneumonia. However, chest X-rays are considered to be the first-line diagnostic test in all patients with suspected pneumonia. This decreases the adoption of microbial diagnostic tests for pneumonia. Additionally, advancements in chest X-ray products to efficiently detect pneumonia could threaten the molecular diagnostic market. Another restraint in the pneumonia testing market is the lack of access to diagnostic facilities in certain regions, particularly in low-income countries and remote areas. Limited availability of infrastructure, trained personnel, and diagnostic equipment can hamper the growth of the market. This can result in delayed, inaccurate results leading to increased morbidity, and mortality rates. These all factors restrict the pneumonia testing market.

Report Coverage:

This research report on the Pneumonia Testing Market has been segmented and sub-segmented based on the Product type, technology, end-user, and region.

By Product Type:

• Analyzers
• Point Of Care (POC)
• Non-POC
• Consumables

Depending on Product type, market growth in the consumables segment will be significant during the forecast period. Consumables used to detect pneumonia contamination include kits and reagents such as PCR assays, nucleic acid detection kits, staining materials, elimination kits, and reagents, standards, and controls. Kits and reagents are routinely used in pneumonia tests and often must be purchased from pharmaceutical companies and biomedical research laboratories. For instance, Plasmo Test, a pneumonia detection kit, performs pneumonia tests, which come with reliable assays. These assays can be repurchased individually or along with the kit. Such factors will increase the market growth during the forecast period. While the POC test offers multiple benefits such as ease of use, and accurate diagnosis. The POC segment is expected to show the highest CAGR during the forecasting period. The growing adoption of POC testing is attributed to higher efficiency, increasing cases of pneumonia, and the rapid test results due to which it is highly preferable.

By Technology:

• Enzyme Linked Immunosorbent Assay (ELISA)
• Immunofluorescence
• Western Blot
• Polymerase Chain Reaction
• Immunohistochemistry
• Molecular diagnostics
• Others

Among these, the Enzyme-Linked Immunosorbent Assay segment dominates the pneumonia testing market and is expected to remain dominant during the forecasting period. This is due to the increased demand for diagnostic techniques and a rise in the number of contract research organizations are the key factors that help to grow the pneumonia testing market.

By End Users:

• Hospitals
• Diagnostic Laboratories
• Homecare
• Others

Among these, the Hospital segment dominates the pneumonia testing market and is expected to remain in a dominant position during the forecasting period. This is due to an increase in the number of patients suffering from pneumonia and being hospitalized due to its seriousness. Diagnostic laboratories hold the second position in market share. The increase in diagnostic centers carrying out tests such as microbial tests from sputum, blood, and urine. Specifically in developing countries, it is expected to have high growth due to the expansion of the diagnostic laboratories segment.

By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Regionally, North America dominates the Pneumonia Testing Market. This is due to the increasing geriatric population in North America region. For instance, according to the Centers for Disease Control and Prevention pneumonia is the eighth leading cause for mortality in the United States which further lead to increased awareness about the disease. Hence increasing geriatric population drive the pneumonia testing market.  Additionally, rising product approval and new product launches are driving the overall market in this region. Furthermore, the increasing healthcare expenditure and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.

The European market has the second largest market share in the pneumonia testing market. The growth can be attributed to the increased number of hospitalizations. The increased government initiatives to raise awareness among people about pneumonia testing. For instance, according to the study published by BMC in January 2021, respiratory diseases in European countries are responsible for 15.0% of in-hospital deaths, with pneumonia being the second most important cause. Also, in terms of 7.0% of hospital admissions, pneumonia comprises a 2.0% share. Thus, the increasing patient pool will likely favor the European market.

The Asia Pacific market is expected to grow significantly during the forecast period. For instance, the rising geriatric population in the Asia Pacific is effectively contributing to the prevalence of pneumonia since the geriatric population is more susceptible to pneumonia. Also, elderly individuals have higher hospitalization rates with a significant impact on morbidity and mortality.

Latin America is expected to have growth due to increasing awareness in recent years. The increasing demand for pneumonia testing in Mexico and Brazil could provide profitable opportunities for the leading market's key players. The Middle East & Africa holds a comparatively lesser share of the market. Still, it is expected to witness growth prospects due to rising awareness and improvement of government policies amongst the people of developing countries in these regions.

Key Market Players:

Some key market players in Pneumonia Testing Market include Thermo Fischer Scientific Inc., BioMerieux SA, Siemens Healthcare, Becton, Dickinson and Co., and Quidel Corp., Abbott, Biorad laboratories, Hologic Inc., Beckman Coulter

Recent Market Happenings:

• On 16^th Dec 2022, Global Access Diagnostics joins consortium to co-develop on-farm rapid test for calf pneumonia, Radical
• DiaSorin and Thermo Fisher Scientific entered into a partnership on B·R·A·H·M·S MR-proADM for precise assessment of disease severity in critical care.